10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
PFIZER INC | |||
Ticker: PFE Fiscal Year: 2010 | |||
Consolidated Statements of Income | |||
Period Ending Dec 31, 2010 10-K (Filed: Feb 28, 2011) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | |
| Revenues | $ 67,809 | 50,009 | 48,296 |
| Costs and expenses: | |||
| Cost of Sales | 16,279 | 8,888 | 8,112 |
| Selling, informational and administrative expenses | 19,614 | 14,875 | 14,537 |
| Research and development expenses | 9,413 | 7,845 | 7,945 |
| Amortization of intangible assets | 5,404 | 2,877 | 2,668 |
| Acquisition-related in-process research and development charges | 125 | 68 | 633 |
| Restructuring charges and certain acquisition - related costs | 3,214 | 4,337 | 2,675 |
| Other deductions - net | 4,338 | 292 | 2,032 |
| Income from continuing operations before provision for taxes on income | 9,422 | 10,827 | 9,694 |
| Provision for taxes on income | 1,124 | 2,197 | 1,645 |
| Income from continuing operations | 8,298 | 8,630 | 8,049 |
| Discontinued operations - net of tax | (9) | 14 | 78 |
| Net income before allocation to noncontrolling interests | 8,289 | 8,644 | 8,127 |
| Less: Net income attributable to noncontrolling interests | 32 | 9 | 23 |
| Net income attributable to Pfizer Inc. | 8,257 | 8,635 | 8,104 |
| Earnings per common share - basic | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.03 | 1.23 | 1.19 |
| Discontinued operations - net of tax (in dollars per share) | 0.01 | ||
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.03 | 1.23 | 1.20 |
| Earnings per common share - diluted | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.02 | 1.23 | 1.19 |
| Discontinued operations - net of tax (in dollars per share) | 0.01 | ||
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.02 | 1.23 | 1.20 |
| Weighted-average shares - basic (in shares) | 8,036 | 7,007 | 6,727 |
| Weighted-average shares - diluted (in shares) | 8,074 | 7,045 | 6,750 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
PFIZER INC | |||
Ticker: PFE Fiscal Year: 2010 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2010 10-K (Filed: Feb 28, 2011) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | |
| Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] | |||
| Operating Activities | |||
| Net income before allocation to noncontrolling interests | $ 8,289 | 8,644 | 8,127 |
| Adjustments to reconcile net income before noncontrolling interests to net cash provided by operating activities: | |||
| Depreciation and amortization | 8,487 | 4,757 | 5,090 |
| Share-based compensation expense | 405 | 349 | 384 |
| Acquisition-related in-process research and development charges | 125 | 68 | 633 |
| Asset write-offs and impairment charges | 3,486 | 305 | 570 |
| Gains on disposals | (155) | (670) | (14) |
| Gains on sales of discontinued operations | (6) | ||
| Deferred taxes from continuing operations | 1,953 | (9,582) | (1,331) |
| Benefit plan contributions (in excess of)/less than expense | (691) | 545 | (49) |
| Other non-cash adjustments | (19) | 199 | (74) |
| Changes in assets and liabilities, net of acquisitions and divestitures: | |||
| Accounts receivable | (608) | 252 | 195 |
| Inventories | 2,917 | 1,631 | 294 |
| Other assets | (896) | (867) | (538) |
| Accounts payable and other liabilities | 827 | 1,502 | 4,310 |
| Other tax accounts, net | (12,666) | 9,454 | 647 |
| Net cash provided by operating activities | 11,454 | 16,587 | 18,238 |
| Investing Activities | |||
| Purchases of property, plant and equipment | (1,513) | (1,205) | (1,701) |
| Purchases of short-term investments with original maturities greater than 90 days | (10,931) | (35,331) | (35,705) |
| Proceeds from redemptions and sales of short-term investments with original maturities greater than 90 days | 4,543 | 42,364 | 27,883 |
| Proceeds from redemptions and sales of short-term investments with original maturities of 90 days or less - net | 5,950 | 5,775 | 7,913 |
| Purchases of long-term investments | (3,920) | (6,888) | (9,357) |
| Proceeds from redemptions and sales of long-term investments | 4,381 | 6,504 | 1,009 |
| Proceeds from redemptions of short-term loans with original maturities greater than 90 days | 1,156 | 1,158 | 625 |
| Issuances of short-term loans with original maturities greater than 90 days | (151) | (565) | (449) |
| Proceeds from redemptions of long-term loans | 356 | 55 | |
| Issuances of long-term loans | (208) | (61) | (501) |
| Acquisitions, net of cash acquired | (273) | (43,123) | (1,184) |
| Other investing activities | 118 | 100 | (1,423) |
| Net cash used in investing activities | (492) | (31,272) | (12,835) |
| Financing Activities | |||
| Increase in short-term borrowings - net | 6,400 | 32,033 | 40,119 |
| Principal payments on short-term borrowings - net | (10,546) | (34,969) | (37,264) |
| Proceeds from issuances of long-term debt | 24,023 | 605 | |
| Principal payments on long-term debt | (6) | (967) | (1,053) |
| Purchases of common stock | (1,000) | (500) | |
| Cash dividends paid | (6,088) | (5,548) | (8,541) |
| Other financing activities | 66 | (91) | 74 |
| Net cash (used in)/provided by financing activities | (11,174) | 14,481 | (6,560) |
| Effect of exchange-rate changes on cash and cash equivalents | (31) | 60 | (127) |
| Net decrease in cash and cash equivalents | (243) | (144) | (1,284) |
| Cash and cash equivalents at beginning of year | 1,978 | 2,122 | |
| Cash and cash equivalents at end of year | 1,735 | 1,978 | 2,122 |
| Supplemental Cash Flow Information | |||
| Non-cash transactions - Acquisition of Wyeth, treasury stock issued | 23,303 | ||
| Cash paid during the period for: | |||
| Income taxes | 11,775 | 2,300 | 2,252 |
| Interest | 2,155 | 935 | 782 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
PFIZER INC | ||
Ticker: PFE Fiscal Year: 2010 | ||
Consolidated Balance Sheets | ||
Period Ending Dec 31, 2010 10-K (Filed: Feb 28, 2011) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2010 | Dec 31, 2009 | |
| Assets | ||
| Cash and cash equivalents | $ 1,735 | 1,978 |
| Short-term investments | 26,277 | 23,991 |
| Accounts receivable, less allowance for doubtful accounts: 2010-$217; 2009-$176 | 14,612 | 14,645 |
| Short-term loans | 467 | 1,195 |
| Inventories | 8,405 | 12,403 |
| Taxes and other current assets | 8,411 | 6,962 |
| Assets held for sale | 561 | 496 |
| Total current assets | 60,468 | 61,670 |
| Long-term investments and loans | 9,748 | 13,122 |
| Property, plant and equipment, less accumulated depreciation | 19,123 | 22,780 |
| Goodwill | 43,947 | 42,376 |
| Identifiable intangible assets, less accumulated amortization | 57,558 | 68,015 |
| Taxes and other noncurrent assets | 4,170 | 4,986 |
| Total assets | 195,014 | 212,949 |
| Liabilities and Shareholders' Equity | ||
| Short-term borrowings, including current portion of long-term debt: 2010-$3,502; 2009-$27 | 5,623 | 5,469 |
| Accounts payable | 4,026 | 4,370 |
| Dividends payable | 1,601 | 1,454 |
| Income taxes payable | 946 | 10,107 |
| Accrued compensation and related items | 2,108 | 2,242 |
| Other current liabilities | 14,305 | 13,583 |
| Total current liabilities | 28,609 | 37,225 |
| Long-term debt | 38,410 | 43,193 |
| Pension benefit obligations | 6,201 | 6,392 |
| Postretirement benefit obligations | 3,035 | 3,243 |
| Noncurrent deferred tax liabilities | 18,648 | 17,839 |
| Other taxes payable | 6,245 | 9,000 |
| Other noncurrent liabilities | 5,601 | 5,611 |
| Total liabilities | 106,749 | 122,503 |
| Preferred stock, without par value, at stated value; 27 shares authorized; issued: 2010-1,279; 2009-1,511 | 52 | 61 |
| Common stock, $0.05 par value; 12,000 shares authorized; issued: 2010-8,876; 2009-8,869 | 444 | 443 |
| Additional paid-in capital | 70,760 | 70,497 |
| Employee benefit trusts | (7) | (333) |
| Treasury stock, shares at cost; 2010-864; 2009-799 | (22,712) | (21,632) |
| Retained earnings | 42,716 | 40,426 |
| Accumulated other comprehensive (loss)/income | (3,440) | 552 |
| Total Pfizer Inc. shareholders' equity | 87,813 | 90,014 |
| Equity attributable to noncontrolling interests | 452 | 432 |
| Total shareholders' equity | 88,265 | 90,446 |
| Total liabilities and shareholders' equity | 195,014 | 212,949 |
| External Links | |
| PFIZER INC (PFE) Fiscal Year 2010 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |